Evotec OAI extends discovery agreement with Solvay
Hamburg-based Evotec OAI has extended its Focused Library Agreement with Solvay Pharmaceuticals, of Abingdon in the UK. Originally signed in January 2001, the agreement has been prolonged by a further year. A team of Evotec OAI chemists will design and synthesise collections of small, drug-like molecules around selected Solvay templates. Solvay will use these compounds in screens against its targets to identify novel drug candidates. Evotec OAI has the potential to earn further clinical and market milestones.
'Over the past two years we have demon-strated that our drug discovery expertise adds significant value to Solvay's programmes. We are delighted that Solvay decided to continue the partnership with Evotec OAI and to become one of our multi-year discovery partners,' said Joern Aldag, president and ceo of Evotec OAI.